Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay
Saved in:
| Title: | Meridian Bioscience Announces Health Canada License for Alethia® CMV Assay |
|---|---|
| Authors: | Meridian Bioscience, Inc. |
| Source: | Business Wire (English). 07/14/2026. |
| Abstract: | Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian's existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian's molecular diagnostic offerings in the Canadian market. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Health Canada has granted a license for its Alethia® CMV assay. The addition of CMV expands Meridian's existing Alethia menu, which includes C. difficile, Group A Strep, Group B Strep, malaria, Mycoplasma, and pertussis assays. This clearance expands Meridian's molecular diagnostic offerings in the Canadian market. [ABSTRACT FROM PUBLISHER] |
|---|
